The Nephrology and Transplantation Update Course is a highly anticipated and well attended pre-congress session of the Australian New Zealand Society of Nephrology (ANZSN) Annual Scientific Meeting that will provide an overview of evidence-based medicine in Nephrology in the past few years. The theme of this year course is “Advances in Nephrology in 2020”.
Healthcare is ever changing with new discoveries, breakthroughs and innovations that significantly transform Nephrology field and improve care for patients with kidney disease throughout the world. As we enter into a new decade, it is useful to pause and review some of the advances and breakthroughs in Nephrology made especially in the past few years.
The course will cover various aspects of nephrology divided into six subtopics, A) Advances in nephrology in 2020, B) Glomerulonephritis, C) End stage kidney disease, D) Acute kidney injury, E) Chronic kidney disease, and F) Transplantation, spread over two days, focusing on hot topics that are likely to have impact on clinical practice. Its target audience are nephrologists, clinicians, fellows and trainees, both locally and internationally. Speakers consist of a mixture of clinicians, researchers and trialists who are experts in their field, with a strong emphasis on translational medicine useful in day-to-day clinical practice.
At the end of the course, participants are expected to have
- A snapshot on the most recent published literature in Nephrology,
- Enhanced knowledge and understanding in various aspects of nephrology, and
- Identify gap in evidence hence promoting future research.
|0730||Update Course Registration|
|DAY 1||NEPHROLOGY & TRANSPLANTATION UPDATE COURSE|
ADVANCES IN NEPHROLOGY IN 2020
At the dawn of 2020, Nephrology fields have made several breakthroughs that include but not limited to the followings: 1) After nearly two decades, a new agent, sodium–glucose cotransporter 2 (SGLT2) inhibitor is proven to prevent loss of kidney function, end-stage kidney disease, hospitalization for heart failure and cardiovascular death in patients with diabetic kidney disease; 2) New discovery has provided an approved treatment to slow the growth of cysts and to preserve kidney function of the most common inherited kidney disease, Autosomal dominant polycystic kidney disease (ADPKD), 3) Several milestones have been made in management of anemia in chronic kidney disease with emerging efficacy and safety evidence of orally available HIF-1a stabilizers, 4). Technical advances in genome sequencing and association studies have yielded critical insights into the genetic architecture of kidney diseases that improve our understanding of the mechanisms of kidney development, homeostasis and disease states, many of which have clinical implications.
|0800-0830||Advance in Management of DKD
|0830-0900||Advance in management of anemia in CKD
Professor Roger is a Consultant Nephrologist and Director at the Renal Unit, Gosford Hospital, Gosford, Australia. He trained initially at Westmead Hospital in Sydney, then researched at St Bartholomew’s Hospital, London, subsequently receiving his Doctorate of Medicine degree from the University of New South Wales, Australia. Professor Roger now has over 30 years’ experience researching anaemia and the role of iron in patients with chronic kidney disease. Full biography
|0900-0930||Advances in genetics in clinical nephrology
Dr Mallawaarachchi is a Clinical Geneticist and Nephrologist, and Staff Specialist at Royal Prince Alfred Hospital, Sydney. Dr Mallawaarachchi is also a Senior Research Scientist in the Division of Genomics and Epigenetics at the Garvan Institute of Medical Research. Her current research focuses on understanding the molecular basis of polycystic kidney disease and is supported by a Viertel Foundation Clinical Investigator Award and The PKD Foundation. She has particular expertise in genomic analysis and variant interpretation and developed with first validated whole-genome sequencing based genetic testing for polycystic kidney disease.
|0930-1000||Breakthrough in management of PKD – ADPKD and ARPKD
Lisa M. Guay-Woodford
Dr. Lisa M. Guay-Woodford is the McGehee Joyce Professor of Pediatrics at the Children’s National Medical Center (CNMC), a pediatric nephrologist, and an internationally-recognized investigator whose research focuses on identifying clinical and genetic factors involved in the pathogenesis of inherited renal disorders, most notably autosomal recessive polycystic kidney disease (ARPKD). Full biography
|1000-1030||Morning Tea Break|
|THEME||DIALYSIS: END STAGE KIDNEY DISEASE (ESKD)
The burden of premature death and health loss from end stage kidney disease (ESKD) is well known. Managing individuals on either haemodialysis or peritoneal dialysis remains a major challenge to the Nephrology community. This session will cover updates in various aspects relating to ESKD including dialysis access, treatment intensity of haemodialysis and regional differences in peritoneal dialysis.
|1030-1100||Dose and frequency of dialysis – which is more important?
Lorraine Kwan (APCN)
Lorraine works as associate consultant in the Department of Medicine, in Queen Mary Hospital and Tung Wah Hospital in Hong Kong. She is also honorary tutor at the Li Ka Shing Faculty of Medicine, the University of Hong Kong. Dr. Kwan received her medical degree from the University of Hong Kong in 2007 and pursued post-graduate training in nephrology in Queen Mary Hospital. Full biography
|1100-1130||Update in access in 2020
Dr Andrea Viecelli is a Senior Lecturer at the Faculty of Medicine, University of Queensland and nephrologist at Princess Alexandra Hospital in Brisbane, Australia. She completed her PhD on strategies to improve vascular access outcomes in patients on haemodialysis through the University of Queensland in 2019. She is a clinical trialist of the Australasian Kidney Trials Network and a lead investigator of the FAVOURED study, an international, multicentre randomised controlled trial of fish oil and aspirin for preventing arteriovenous fistula failure. Full biography
|1130-1200||Update in peritoneal dialysis
Sunita Bavanandan (APCN)
Dr.Sunita Bavanandan graduated from the University of Queensland Australia in December, 1991. She obtained her qualifications as a Member of the Royal College of Physicians United Kingdom in 1997 and became a Fellow of the Royal College of Physicians Edinburgh in 2007. From 2003-2004 she obtained further training at the Leicester General Hospital, United Kingdom. Special interests are in Chronic Kidney Disease, Hypertension, Diabetic Kidney Disease and Peritoneal Dialysis. Full biography
GENERAL NEPHROLOGY: GLOMERULONEPHRITIS
Despite regional difference, glomerulonephritis accounts for nearly a quarter of all cases of chronic kidney disease worldwide. It remains one of the leading cause of end stage kidney disease. Over the past decades, significant advances have been made in the management of glomerulonephritis especially in IgA nephropathy, focal segmental glomerulosclerosis, and ANCA-associated glomerulonephritis. However, several controversies remain in the best practice treatment for these common forms of kidney disease. This session will cover some of the advances in treatment and controversies for glomerulonephritis in 2020.
|1300-1330||Role of endothelin receptor antagonist in proteinuric kidney disease
Muh Geot Wong
Dr Wong obtained his MBBS in 2000 follows by MRCP (UK) and Nephrology training in Malaysia before migrating to Australia where he obtained his Fellowship in Nephrology and a PhD in Medicine from the University of Sydney in 2010. He is currently a Renal Staff Specialist at the Royal North Shore Hospital (RNSH), and a Senior Clinical Lecturer of University of Sydney and University of NSW. Full biography
|1330-1400||Novel therapy in IgA nephropathy
Yusuke Suzuki (APCN)
Yusuke Suzuki is currently Professor of Department of Nephrology in Graduate School of Juntendo University. His academic positions include Directors of Japanese Society of Nephrology (JSN), Councilor of Japanese Society of Internal Medicine, Japanese Society of Dialysis Therapy, Japanese Society of Hypertension, ISN council, ISN Deputy Chair of North and East Asia Regional Board, Liaison officer in ISN sister renal center program for JSN/Vietnam, Chief Researcher of Special Research Group of IgA Nephropathy in Progressive Renal Diseases Research from the Ministry of Health, Labor and Welfare of Japan, Chief Researcher of biomarker project on IgA nephropathy from Research on Intractable Disease from Japan Agency for Medical Research and Development. Full biography
|1400-1430||Update in management of ANCA vasculitis
|1430-1500||Afternoon Tea Break|
|THEME||GENERAL NEPHROLOGY: ACUTE KIDNEY INJURY (AKI)
Recent epidemiological and mechanistic studies suggest that chronic kidney disease and acute kidney injury are closely interconnected — acute kidney injury is increasingly recognised as a risk factor for chronic kidney disease. This session will cover the recent advances in AKI covering broad aspects from intravenous fluid replacement, cardiorenal syndrome and long term sequelae of AKI.
|1500-1530||Is sodium chloride the best replacement fluid?
|1530-1600||Long term sequelae of acute kidney injury
Emily See is a Critical Care Nephrologist and Research Fellow in the Department of Intensive Care at Austin Health, Melbourne. She completed her renal training at University Hospital Geelong, Princess Alexandra Hospital, and Monash Health, and is currently undertaking a PhD examining the long-term sequelae of acute kidney injury, with the aim of developing an evidence-based model of care for high-risk survivors. Full biography
|1600-1630||Decision-making for ESRD in the elderly
Rajesh is a Nephrologist trained in India. He moved to Launceston in 2009 and established the renal supportive care service at the Launceston General Hospital in 2011. Full biography
SPEED NETWORKING RECEPTION
Join other update course participants and our theme sponsors for 30 minutes of small group networking meets and greets. Each virtual meeting is 5 minutes in length, then you will be randomly reallocated to another group. A great way to catch up with old friends and meet new colleagues!
|0730||Update Course Registration|
|DAY 2||NEPHROLOGY & TRANSPLANTATION UPDATE COURSE|
|THEME||GENERAL NEPHROLOGY: CHRONIC KIDNEY DISEASE (CKD)
Management of CKD and its complications remain on-going challenges for nephrologists. This session will cover topics including advances in imagining in management of CKD, use of binders in CKD, including an innovative way of learning electrolytes.
|0800-0830||Role of potassium and uremic binder in management of CKD
Dr Suet-Wan Choy completed her medical degree at Melbourne University with honours. She is a Nephrologist, General Physician and an Obstetric Medicine Physician with public clinical appointments at Austin Health, Eastern Health and the Mercy Hospital for Women.
After completing her PhD at the Austin Hospital, University of Melbourne, Suet-Wan undertook a post-doctoral research fellowship at the Pittsburgh Center for Kidney Research, Renal-Electrolyte Division, Department of Medicine, University of Pittsburgh School of Medicine, Pennsylvania, USA.
|0830-0900||Diagnosis and management of cardiorenal sydnrome
|0900-0930||Advances in imaging in CKD
Patrick (Paddy) Mark is Professor of Nephrology and Honorary Consultant Nephrologist at the Glasgow Renal and Transplant Unit based at the Queen Elizabeth University Hospital Glasgow. He was appointed as Clinical Senior Lecturer in 2011 following clinical training in Medicine and Nephrology combined with a Clinical Lecturer post between 2006-2011. He was promoted to Reader in 2015 and to Professor in 2018. He leads the United Kingdom Cardio-Renal Clinical Study Group, as part of the United Kingdom Kidney Research Consortium. Full biography
|0930-1000||New ways to learn electrolyte and acid base
|1000-1030||Morning Tea Break|
|THEME||TSANZ-ANZSN combined TRANSPLANTATION session “What did we learn in kidney transplantation in 2020?”
Kidney transplantation is considered the treatment of choice for individuals with severe chronic kidney disease due to improved quality of life and survival when compared to individuals receiving dialysis. This half-day session is a combined effort of TSANZ and ANZSN in providing an essential updates on relevant topics for non-transplant nephrologists. This session covers relevant topics in kidney transplantation for donor and recipient perspective, from pre-transplant assessment to post-transplant management as well as the paired kidney exchange program.
|1030-1100||Pre-transplant Immunological assessment and management
|1100-1130||Frailty in kidney transplantation – when to say no?
|1130-1200||Pre-transplant management of overweight/obesity in potential kidney recipient
|1200-1230||Controversies in living donation/high risk kidney donation
To be advised
|THEME||TSANZ-ANZSN combined TRANSPLANTATION session “What did we learn in kidney transplantation in 2020?” – continued
|1330-1400||Acute and chronic antibody mediated rejection – what should you know?
|1400-1430||Post-transplant recurrence of primary disease including AHUS
|1430-1500||Kidney transplant histology 101
|1500-1530||Paired kidney exchange program review
|1530-1600||Afternoon Tea Break|